Abstract
Alcohol use disorder (AUD) remains a significant healthcare challenge due to its high prevalence, clinical complexity, and contribution to preventable illness and mortality worldwide. Despite widespread alcohol consumption and increasing healthcare utilization related to intoxication and chronic disease, treatment access remains limited, and current therapies primarily focus on behavioral modification or central nervous system pathways rather than addressing the physiological damage caused by alcohol metabolism.
The scientific foundation of alcohol-related harm centers on how ethanol is metabolized in the body. Alcohol is converted into acetaldehyde, a toxic intermediate that promotes oxidative stress, inflammation, mitochondrial dysfunction, and cellular injury. Variability in metabolic enzymes, influenced by genetics, liver health, and nutritional status, contributes to differences in intoxication severity and long-term health outcomes among individuals. Current pharmacologic treatments do not accelerate alcohol clearance or directly reduce metabolic toxicity, leaving an important gap in care.
The white paper introduces a patented Alcohol Metabolism Acceleration Composition designed to support endogenous enzymatic pathways involved in alcohol breakdown. By enhancing the function of alcohol dehydrogenase and aldehyde dehydrogenase, and incorporating antioxidant and metabolic cofactors, the composition aims to reduce acetaldehyde accumulation, shorten exposure to toxic metabolites, and promote metabolic balance. The proposed mechanism extends beyond liver detoxification and may influence systemic pathways, including gut-liver-brain interactions linked to cognitive and inflammatory effects.
Potential clinical applications include acute care settings, harm reduction strategies, and supportive use in individuals with metabolic vulnerability or limited treatment options. However, ethical and regulatory considerations emphasize that such interventions must be positioned as adjunctive tools rather than substitutes for treatment or encouragement of alcohol consumption. Safety monitoring, responsible use frameworks, and continued research are essential.
Overall, the paper highlights enzyme-driven metabolic support as an emerging innovation in healthcare. By targeting the physiological processes underlying alcohol-related harm, this approach may complement existing therapies, improve patient safety, and contribute to future advancements in precision medicine and harm reduction strategies.
References
- Addolorato G., et al. “Treatment of alcohol use disorders in patients with alcoholic liver disease”. Journal of hepatology 65.3 (2016): 618-630.
- Carvalho AF., et al. “Alcohol use disorders”. The Lancet 394.10200 (2019): 781-792.
- Cederbaum AI. “Alcohol metabolism”. Clinics in liver disease 16.4 (2012): 667-685.
- Cederbaum AI, Lu Y and Wu D. “Role of oxidative stress in alcohol-induced liver injury”. Archives of toxicology 83.6 (2009): 519-548.
- Centers for Disease Control and Prevention (CDC). Alcohol Use and Your Health (2025). https://www.cdc.gov/alcohol
- Collins SE., et al. “Randomized controlled trial of harm reduction treatment for alcohol (HaRT-A) for people experiencing homelessness and alcohol use disorder”. International Journal of Drug Policy 67 (2019): 24-33.
- Crabb DW., et al. “Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology”. Proceedings of the nutrition society 63.1 (2004): 49-63.
- Gao B and Tsukamoto H. “Inflammation in alcoholic and non-alcoholic fatty liver disease: friend or foe?”. Gastroenterology 150.8 (2016): 1704-1709.
- Lee JY., et al. “Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD”. Antioxidants 14.10 (2025): 1196.
- Litten RZ., et al. “Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development”. Alcoholism: Clinical and Experimental Research 40.7 (2016): 1368-1379.
- Mayo Clinic. Alcohol use disorder: Symptoms and causes (2022). https://www.mayoclinic.org/diseases-conditions/alcohol-use-disorder/symptoms-causes/syc-20369243
- National Institute on Alcohol Abuse and Alcoholism (NIAAA). Understanding alcohol use disorder (2025a). https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder
- National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol facts and statistics. Alcohol Use in the United States: Age Groups and Demographic Characteristics (2025b). https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics
- Osna NA, Donohue Jr TM and Kharbanda KK. “Alcoholic liver disease: pathogenesis and current management”. Alcohol research: current reviews 38.2 (2017): 147.
- Rehm J., et al. “Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union”. European Neuropsychopharmacology 23.2 (2013): 89-97.
- Seitz HK., et al. “Publisher correction: alcoholic liver disease”. Nature Reviews Disease Primers 4.1 (2018): 18.
- Stickel F., et al. “The genetics of alcohol dependence and alcohol-related liver disease”. Journal of hepatology 66.1 (2017): 195-211.
- U.S. Patent and Trademark Office. Alcohol metabolism acceleration composition (U.S. Patent No. 11,896,608 B1) (2024).
- World Health Organization (WHO). Global status report on alcohol and health and treatment of substance use disorders (2024). https://iris.who.int/server/api/core/bitstreams/32b161e9-5683-40f5-a1c3-1c92a76d5cda/content
- Wu D and Cederbaum AI. “Alcohol, oxidative stress, and free radical damage”. Alcohol research & health 27.4 (2003): 277.